Fresenius stock gains as mAbxience deal adds biosimilar scale

Published on 10/05/2026 at 14:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock was trading at EUR 44.35 on October 5, 2026, as the company completed its mAbxience takeover. Q2 core EPS rose 14 percent to EUR 0.83.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock (ISIN DE000FRE5EN2) was trading at EUR 44.35 on Xetra on October 5, 2026, up 1.65 percent, while the healthcare group completed its takeover of mAbxience. According to EQS News on October 1, 2026, Fresenius acquired the remaining 45 percent of the biosimilars company for total consideration of up to EUR 750 million.

Full ownership expands biosimilars control

The transaction was signed and completed on September 30, 2026, with EUR 50 million of the consideration linked to site approvals. The deal gives Fresenius full ownership of a platform that covers biosimilar research, manufacturing, regulatory work and commercialization.

EQS News reports that the acquisition should immediately increase Group core earnings per share and raise net debt to EBITDA by 20 basis points. mAbxience generated more than EUR 320 million in revenue in fiscal year 2025 and has four products on the market plus eight candidates in development.

Q2 growth supports the higher outlook

Fresenius entered the deal after a stronger second quarter. In Q2 2026, Fresenius reported group revenue of EUR 5,864 million, up 6 percent organically from EUR 5,571 million in Q2 2025.

The same Q2 2026 release showed group EBIT of EUR 719 million, up 10 percent in constant currency, and core net income of EUR 470 million, up 14 percent. Core EPS increased 14 percent to EUR 0.83 from EUR 0.73, giving the mAbxience deal a stronger earnings backdrop.

Analysts see more room above the price

According to MarketScreener on September 17, 2026, the consensus rating was Buy from 14 analysts, with an average price target of EUR 55.59. The same page reported that UBS kept a Buy rating and a EUR 56 target, placing analyst expectations above the current Xetra quotation.

Fresenius stock stays below its yearly high

At EUR 44.35 on October 5, 2026, Fresenius stock stood 16.26 percent below its 52-week high of EUR 52.96 and above its 52-week low of EUR 35.11. The market capitalization was EUR 25.0 billion, with 157,442 shares traded at the recorded time.